PL3953357T3 - Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA - Google Patents
Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRAInfo
- Publication number
- PL3953357T3 PL3953357T3 PL20721083.2T PL20721083T PL3953357T3 PL 3953357 T3 PL3953357 T3 PL 3953357T3 PL 20721083 T PL20721083 T PL 20721083T PL 3953357 T3 PL3953357 T3 PL 3953357T3
- Authority
- PL
- Poland
- Prior art keywords
- pdgfra
- mediated diseases
- pyrrolotriazine derivatives
- treating kit
- kit
- Prior art date
Links
- 101150038994 PDGFRA gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833529P | 2019-04-12 | 2019-04-12 | |
| US201962911016P | 2019-10-04 | 2019-10-04 | |
| US201962930240P | 2019-11-04 | 2019-11-04 | |
| PCT/US2020/027177 WO2020210293A1 (en) | 2019-04-12 | 2020-04-08 | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3953357T3 true PL3953357T3 (pl) | 2024-09-02 |
Family
ID=70416596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20721083.2T PL3953357T3 (pl) | 2019-04-12 | 2020-04-08 | Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20220153748A1 (pl) |
| EP (2) | EP4424312A3 (pl) |
| JP (2) | JP7600140B2 (pl) |
| KR (1) | KR102875260B1 (pl) |
| CN (1) | CN113939515B (pl) |
| AU (1) | AU2020272743B2 (pl) |
| BR (1) | BR112021020441A2 (pl) |
| CA (1) | CA3136802A1 (pl) |
| CL (1) | CL2021002656A1 (pl) |
| CO (1) | CO2021015113A2 (pl) |
| DK (1) | DK3953357T3 (pl) |
| EC (1) | ECSP21080096A (pl) |
| ES (1) | ES2980811T3 (pl) |
| FI (1) | FI3953357T3 (pl) |
| HR (1) | HRP20240702T1 (pl) |
| HU (1) | HUE067299T2 (pl) |
| IL (1) | IL287168B2 (pl) |
| LT (1) | LT3953357T (pl) |
| MA (1) | MA55604B1 (pl) |
| MD (1) | MD3953357T2 (pl) |
| MX (1) | MX2021012469A (pl) |
| MY (1) | MY209048A (pl) |
| PE (1) | PE20212331A1 (pl) |
| PH (1) | PH12021552568A1 (pl) |
| PL (1) | PL3953357T3 (pl) |
| PT (1) | PT3953357T (pl) |
| RS (1) | RS65644B1 (pl) |
| SG (1) | SG11202111244XA (pl) |
| SI (1) | SI3953357T1 (pl) |
| SM (1) | SMT202400229T1 (pl) |
| TW (1) | TWI857043B (pl) |
| WO (1) | WO2020210293A1 (pl) |
| ZA (1) | ZA202108104B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7710223B2 (ja) * | 2018-04-16 | 2025-07-18 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 |
| AU2020272743B2 (en) * | 2019-04-12 | 2025-10-16 | Blueprint Medicines Corporation | Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases |
| WO2022081626A1 (en) * | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| US20240010652A1 (en) * | 2020-10-14 | 2024-01-11 | Blueprint Medicines Corporation | Compositions and methods for treating kit- and pdgfra-mediated diseases |
| HU231413B1 (hu) | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| CA3210747A1 (en) | 2021-03-03 | 2022-09-09 | Christopher Lee | Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases |
| CR20230479A (es) | 2021-03-10 | 2024-03-08 | Blueprint Medicines Corp | Formas de sales y sólidas de un inhibidor de cinasas |
| CN113278023B (zh) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | 含氮杂环化合物及其制备方法和应用 |
| KR20240115979A (ko) * | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
| WO2024171143A1 (en) | 2023-02-17 | 2024-08-22 | Assia Chemical Industries Ltd. | Salts and solid forms of elenestinib |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| WO2000071129A1 (en) | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| HRP20040988A2 (en) | 2002-04-23 | 2005-06-30 | Bristol-Myers Squibb Company A Delaware (Usa) Corp | Pyrrolo-triazine aniline compounds useful as kinas |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| BRPI0407811A (pt) | 2003-02-27 | 2006-02-14 | Uriach Y Compania S A J | composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| WO2006028524A2 (en) | 2004-04-29 | 2006-03-16 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| AU2007209689B2 (en) | 2006-01-27 | 2012-03-15 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors |
| BRPI0714359A2 (pt) | 2006-07-07 | 2013-02-26 | Bristol-Myers Squibb Company | inibidores de pirrolotriazina cinase |
| KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| MX2010010151A (es) | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| US20130023497A1 (en) | 2009-06-08 | 2013-01-24 | Chunlin Tao | Triazine Derivatives and their Therapeutical Applications |
| EP2532659A1 (en) | 2009-07-07 | 2012-12-12 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011103196A1 (en) | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| WO2014039714A2 (en) | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| BR112015014752B1 (pt) | 2012-12-21 | 2022-07-05 | Plexxikon, Inc | Compostos e seus uso para modulação de cinase |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| ES2683127T3 (es) | 2013-10-17 | 2018-09-25 | Blueprint Medicines Corporation | Composiciones útiles para tratar trastornos relacionados con la KIT |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| MX2018001032A (es) | 2015-07-24 | 2018-11-09 | Blueprint Medicines Corp | Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr. |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| TW202039862A (zh) | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| AU2020272743B2 (en) * | 2019-04-12 | 2025-10-16 | Blueprint Medicines Corporation | Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
-
2020
- 2020-04-08 AU AU2020272743A patent/AU2020272743B2/en active Active
- 2020-04-08 US US17/602,770 patent/US20220153748A1/en active Pending
- 2020-04-08 SM SM20240229T patent/SMT202400229T1/it unknown
- 2020-04-08 SG SG11202111244XA patent/SG11202111244XA/en unknown
- 2020-04-08 MX MX2021012469A patent/MX2021012469A/es unknown
- 2020-04-08 PE PE2021001699A patent/PE20212331A1/es unknown
- 2020-04-08 LT LTEPPCT/US2020/027177T patent/LT3953357T/lt unknown
- 2020-04-08 JP JP2021560255A patent/JP7600140B2/ja active Active
- 2020-04-08 US US16/842,969 patent/US10829493B2/en active Active
- 2020-04-08 CN CN202080042732.0A patent/CN113939515B/zh active Active
- 2020-04-08 IL IL287168A patent/IL287168B2/en unknown
- 2020-04-08 BR BR112021020441A patent/BR112021020441A2/pt unknown
- 2020-04-08 PL PL20721083.2T patent/PL3953357T3/pl unknown
- 2020-04-08 KR KR1020217036868A patent/KR102875260B1/ko active Active
- 2020-04-08 WO PCT/US2020/027177 patent/WO2020210293A1/en not_active Ceased
- 2020-04-08 FI FIEP20721083.2T patent/FI3953357T3/fi active
- 2020-04-08 EP EP24170331.3A patent/EP4424312A3/en active Pending
- 2020-04-08 MY MYPI2021006079A patent/MY209048A/en unknown
- 2020-04-08 SI SI202030454T patent/SI3953357T1/sl unknown
- 2020-04-08 TW TW109111858A patent/TWI857043B/zh active
- 2020-04-08 CA CA3136802A patent/CA3136802A1/en active Pending
- 2020-04-08 PT PT207210832T patent/PT3953357T/pt unknown
- 2020-04-08 MA MA55604A patent/MA55604B1/fr unknown
- 2020-04-08 DK DK20721083.2T patent/DK3953357T3/da active
- 2020-04-08 HR HRP20240702TT patent/HRP20240702T1/hr unknown
- 2020-04-08 HU HUE20721083A patent/HUE067299T2/hu unknown
- 2020-04-08 RS RS20240664A patent/RS65644B1/sr unknown
- 2020-04-08 ES ES20721083T patent/ES2980811T3/es active Active
- 2020-04-08 MD MDE20220189T patent/MD3953357T2/ro unknown
- 2020-04-08 EP EP20721083.2A patent/EP3953357B1/en active Active
-
2021
- 2021-04-08 PH PH1/2021/552568A patent/PH12021552568A1/en unknown
- 2021-10-12 CL CL2021002656A patent/CL2021002656A1/es unknown
- 2021-10-21 ZA ZA2021/08104A patent/ZA202108104B/en unknown
- 2021-11-09 CO CONC2021/0015113A patent/CO2021015113A2/es unknown
- 2021-11-12 EC ECSENADI202180096A patent/ECSP21080096A/es unknown
-
2024
- 2024-12-03 JP JP2024210028A patent/JP2025029094A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287168A (en) | Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra | |
| IL277190A (en) | Methods of treating HPV-related diseases | |
| IL277333A (en) | Methods for treating eye diseases | |
| LT3728271T (lt) | Makrocikliniai junginiai, skirti ligų gydymui | |
| IL287907A (en) | Cancer treatment methods | |
| IL291735A (en) | Heteroarylbiphenylamines for the treatment of pd-l1 diseases | |
| SG11202112800SA (en) | Illumination for photodynamic therapy | |
| IL323370A (en) | Development of indazolyl-isoxazole for cancer treatment | |
| EP4034128A4 (en) | TUMOR REGRESSION INDUCTION METHOD | |
| IL291565A (en) | A method for treating phenylalanine irregularity | |
| IL276639A (en) | Materials and methods for the treatment of dysproliferative diseases | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| GB201908885D0 (en) | Therapeutic compounds | |
| SG11202110659SA (en) | Method for treating ocular diseases | |
| IL289436A (en) | Methods for treating eye diseases | |
| EP4058063A4 (en) | METHODS OF TREATMENT OF DISEASES | |
| GB201909466D0 (en) | Compounds for treating cancer | |
| HK40076432A (en) | Compounds and methods for treating oxalate-related diseases | |
| HK40123763A (zh) | 适用於治疗心血管疾病的新型化合物 | |
| HK40072711A (en) | Dosing regimens for treating or preventing c5-associated diseases | |
| HK40078516A (zh) | 诱导肿瘤消退的方法 | |
| HK40067840A (en) | Methods for treating ocular diseases | |
| HK40058903A (en) | Therapeutic methods for treating hepatitis b | |
| GB201911574D0 (en) | Therapeutic compounds |